News

May 9, 2016

Effective today, Merck KGaA, Darmstadt, Germany, will have non-exclusive global marketing and commercialization rights to Progyny's Early Embryo Viability Assessment Test, or Eeva® Test...

October 19, 2015

Progyny, the leading company dedicated to helping ensure patients control their fertility journey and achieve the best possible outcomes, announced today that new clinical research data associated with use of its Eeva™ Test will be highlighted this week during scientific sessions at the American Society for Reproductive Medicine (ASRM) in Baltimore, MD.

October 16, 2015

Progyny, the leading company dedicated to helping ensure patients control their fertility journey and achieve the best possible outcomes, announced today new insights on factors associated with increased likelihood of acceptance of elective single embryo transfer (eSET) for patients undergoing IVF from a nationwide IVF patient survey will be presented at the American Society for Reproductive Medicine (ASRM) in Baltimore, MD.

August 5, 2015

A slew of new tech companies are hoping to hit it big by making it easier and cheaper for people to have children.

April 26, 2015

The Eeva Test is now commercially available in the United States following its recent FDA clearance. This breakthrough technology is designed...

April 16, 2015

A new test aims to improve the subjective visual practice of embryo selection in vitro fertilization with better imaging and data.

March 26, 2015

PR Newswire- March 26, 2015, NEW YORK, NY- The Eeva Test is now commercially available in the United States following its recent FDA clearance. This breakthrough technology is designed to help fertility clinics select the best embryos during in vitro fertilization (IVF) to aid in their effort to provide the best chance of a successful pregnancy.

February 15, 2015

Every one of us started out as a single cell, dividing into two, then three and four cells during the first two days after fertilization. But only a few early embryos – about one in three – have a genetic makeup that’s good enough to let them continue their development....

October 20, 2014

PRNewswire- October, 20, 2014, HONOLULU- Auxogyn, a company focused on advancing women's reproductive health by translating scientific discoveries into clinical solutions, today announced oral presentations of the latest data on its Eeva™ Test this week at the 70th Annual Meeting of the American Society For Reproductive Medicine (ASRM) 2014 being held this week in Honolulu, Hawaii.

October 15, 2014

PRNewswire- Oct. 15, 2014- Auxogyn, a leader in women's reproductive health, and RESOLVE: The National Infertility Association today announced their joint sponsorship of a panel discussion on Elective Single Embryo Transfer (eSET) on October 20th. The panel discussion entitled “Understanding Patients’ Perspectives on Elective Single Embryo Transfer” will shares the Nationwide IVF Patient Survey results with Physicians to Help Improve Patient Education

October 13, 2014

Auxogyn, Inc. a company focused on advancing women’s reproductive health by translating scientific discoveries into clinical solutions, today announced that Brigham and Women’s Center for Infertility and Reproductive Surgery (CIRS) has initiated its Pregnancy Pilot Study using the Eeva™ System. The Pregnancy Pilot Study is a single-site randomized controlled trial designed to gather pilot data to evaluate the effect of use of the Eeva Test on clinical pregnancy rates in IVF patients who undergo elective single embryo transfer (eSET).

August 4, 2014

Auxogyn, a leader in women’s reproductive health and the developer of the Eeva Test, a test clinically proven to assess embryos with the highest development potential for transfer, presented a check for £2000 to Infertility Network UK (I N UK), a patient charity solely devoted to help people who are struggling to conceive, following its successful social media fundraising campaign #BSOCIAL4INUKheld during May and June of this year.

July 17, 2014

Lead embryologist, Adam Burnley from the Bourn Hall Clinic in the UK is talking about the IVF technologies used at Bourn Hall, including the Eeva Test. Bourn Hall was the first IVF clinic in the world.

July 11, 2014

Annika Levitt initially resisted the fertility clinic’s suggestion that only one embryo- rather than the usual two or more- be transferred to her uterus because she was too small to risk carrying more than one baby.

July 1, 2014

Auxogyn, a leader in women’s reproductive health, announced today that they will present their latest Eeva™ Test data at the 30th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE) 2014.

June 10, 2014

Auxogyn, Inc. a leader in women’s reproductive health, announced today that its first product, the Eeva System, has received clearance from the U.S. Food and Drug Administration through its de novo classification process, a regulatory pathway for select novel, low- to moderate-risk medical devices that are first-of-a-kind.

May 6, 2014

The Eeva™ Test is launching its Be Social (#BSOCIAL4INUK) campaign to raise money for Infertility Network UK (I N UK), a patient charity solely devoted to help, support and provide information to people who are struggling to conceive.

April 3, 2014

Merck Serono, the biopharmaceutical division of Merck KGaA, Darmstadt, Germany, will receive commercialization rights from Auxogyn for the Eeva Test, which is designed to provide objective embryo viability data to IVF clinicians. Agreement reflects Merck Serono’s and Auxogyn’s commitment to bringing innovative technologies to the IVF community designed to help improve patient outcomes.

February 28, 2014

IVF Spain has also been the first clinic in introducing EEVA (Early Embryo Viability Assessment test), which is an extra tool for the embryologists to select the best embryo for transfer.

January 29, 2014

MARKETWIRED- January, 29, 2014- VANCOUVER, B.C.- Genesis Fertility Center, an in vitro fertilization (IVF) clinic in Vancouver, announced today that it is the first clinic in Canada, and the first commercial clinic in North America, to offer patients the Early Embryo Viability Assessment (Eeva) Test.

January 6, 2014

PRNewswire- January. 6, 2014- Results of a clinical study utilizing the Auxogyn's Eeva™ Technology were presented today at the 2014 Association of Clinical Embryologists (ACE) conference. The results showed similar pregnancy rates seen with day 3 transfer incorporating Eeva Results in Embryo Selection Versus Day 5 Transfer Utilizing Only Morphological Assessment.

November 1, 2013

SCIAD- November, 1st, 2013- LONDON, UK- With an increasing number of UK couples travelling abroad for fertility treatment and Spain being among the most popular of the preferred destinations, both FIV Marbella and IVF Spain are proud to be the first infertility clinics to make a ground-breaking new approach to IVF commercially available in Spain

October 31, 2013

Taking a close up look of the Early Embryo Viability Assessment at the SIMS Clinic in Dublin.

July 9, 2013

London, UK – July 9, 2013 – Auxogyn, Inc., a privately held company that is revolutionizing the field of reproductive medicine by translating scientific discoveries in early embryo development into effective clinical tools, has been selected as the recipient of the prestigious Merck Serono Grant for Fertility Innovation (GFI) award. The award was announced at the 29th Annual Meeting of the European Society of Human Reproduction and Embryology (ESHRE).

July 3, 2013

PRNewswire- July, 3, 2013- MENLO PARK, CA- Auxogyn, Inc., a company focused on revolutionizing the field of reproductive medicine by providing novel scientific and clinically validated solutions to IVF clinicians and their patients, today announced the presentations of the latest data on its Eeva™ Test at the 29th annual meeting of the European Society of Human Reproduction and Embryology (ESHRE). The meeting will be held July 7 through 10 in London, UK.

June 14, 2013

PRNewswire- June 14, 2013- MENLO PARK, CA- Auxogyn announces the birth of the first baby in Scotland to be born using a ground-breaking new approach to IVF, the 'Early Embryo Viability Assessment' (Eeva™) test, that improves embryo selection.

June 5, 2013

Auxogyn is at the forefront of revolutionizing IVF treatment. Today, Auxogyn, Inc. announced the birth of one of the first babies to be born after embryologists used the Early Embryo Viability Assessment (Eeva™) Test to select and identify the most viable embryo for implantation into the mother’s womb. The Hewitt Fertility Center in Liverpool, UK, where the baby was born on 31st May 2013, is one of six IVF clinics in the UK offering the Eeva test to parents as part of an enhanced IVF treatment.

May 7, 2013

The cutting-edge, new Early Embryo Viability Assessment™ (Eeva) Test designed to improve in vitro fertilization (IVF) outcomes is now available to couples seeking IVF treatment in East England. Using intelligent computer vision software to analyze key scientifically and clinically validated cell-division parameters, the Eeva Test is the first and only non-invasive IVF test clinically proven to help IVF teams determine which embryos have the best potential to grow to the blastocyst stage, a critical milestone in embryo development.

March 26, 2013

Revolutionary new non-invasive procedure uses intelligent imaging software to measure and predict with high accuracy which embryos will likely grow to the blastocyst stage (day 5-6), a critical milestone in embryo development.

January 24, 2013

MARKETWIRE- January, 24, 2013- MENLO PARK, CA- Auxogyn Inc. today announced that Sims IVF is the first fertility clinic in Ireland to offer patients the Early Embryo Viability Assessment (Eeva) Test. The Eeva Test is designed to improve in vitro fertilization (IVF) outcomes by providing clinicians and patients with objective information that will enable them to predict embryo viability with a new level of accuracy.

January 11, 2013

Following the birth of the first Eeva baby conceived at the Glasgow Center for Reproductive Medicine (GCRM), one of the UK’s most innovative IVF clinics and supporter of National Infertility Awareness Week, the clinic identifies the benefits of using the ‘Early Embryo Viability Assessment’ (Eeva) test, a ground-breaking new approach to IVF that improves embryo selection.

January 3, 2013

MARKETWIRE- January, 3, 2013- MENLO PARK, CA- Auxogyn, Inc., a company focused on revolutionizing the field of reproductive health, today announced that the European Patent Office has issued a notice of intention to grant a patent to Stanford University that will cover certain predictive parameters for the assessment of embryo viability during in vitro fertilization (IVF) procedures used in Auxogyn’s Early Embryo Viability Assessment (Eeva) Test. In addition, the U.S. Patent and Trademark Office (USPTO) has issued a third U.S. patent that also covers predictive parameters used in the assessment of embryo viability during IVF procedures. Auxogyn is the exclusive licensee of both patents.

December 4, 2012

Auxogyn, Inc., a company focused on revolutionizing the field of reproductive health, today announced that research involving the use of the company’s flagship product, the Early Embryo Viability Assessment (Eeva) Test, was recognized by the Fertility Society of Australia at its 2012 Scientific Meeting with the Ferring “Best Scientific Paper Award.”

October 22, 2012

Auxogyn, Inc., a company focused on revolutionizing the field of reproductive health, today announced two presentations describing new data from a prospective, cohort study conducted at multiple independent centers. The data was presented today in oral sessions during the ASRM Annual Meeting in San Diego. The Eeva(TM) Test uses intelligent computer vision software to measure key parameters from video images and predicts with high accuracy at the cleavage stage which embryos will likely grow to the blastocyst stage.

October 18, 2012

Merck Serono, a division of Merck, Darmstadt, Germany, and Auxogyn, Inc., a company focused on revolutionizing the field of reproductive health, today announced that they have entered into a strategic agreement focused on Auxogyn's proprietary Early Embryo Viability Assessment (Eeva) Test. Under the terms of the agreement, Merck Serono will provide strategic, scientific and medical support in the development and commercialization of the Eeva™ Test.

October 11, 2012

MARKETWIRE- October, 11, 2012- MENLO PARK, CA- Auxogyn, Inc., a company focused on revolutionizing the field of reproductive health, today announced that the U.S. District Court for the Northern District of California has ruled in favor of Auxogyn and Stanford University and dismissed a patent lawsuit initiated by Unisense Fertilitech. Auxogyn is the exclusive licensee of this patent from Stanford University.

September 17, 2012

Auxogyn, Inc., a company focused on revolutionizing the field of reproductive health, today announced the launch of its Early Embryo Viability Assessment (Eeva) Test in the European Union (EU), with the first installation at the Hewitt Fertility Center in Liverpool. The Eeva™ Test is designed to improve in vitro fertilization (IVF) outcomes by providing clinicians and patients with objective information that will enable them to predict embryo viability with a new level of accuracy.

July 23, 2012

Auxogyn, Inc., a company focused on revolutionizing the field of reproductive health, today announced that it has received CE mark approval to market its flagship product, the Early Embryo Viability Assessment (Eeva) Test, which is designed to improve in vitro fertilization (IVF) outcomes by providing clinicians and patients with objective information that will enable them to predict embryo viability with a new level of accuracy.

July 2, 2012

MARKETWIRED- July, 2nd, 2012- MENLO PARK, CA- Auxogyn, Inc., a company focused on revolutionizing the field of reproductive health, today presented data showing the ability of its flagship product, the Early Embryo Viability Assessment (Eeva) Test, to predict embryo advancement with a new level of accuracy. The Eeva(TM) Test uses intelligent computer vision software to measure key parameters from video images and predicts with high accuracy at the cleavage stage which embryos will likely grow to the blastocyst stage. These clinical data were presented today at the European Society of Human Reproduction and Embryology (ESHRE) Annual Meeting in Istanbul, Turkey.

July 5, 2011

Auxogyn, Inc., a privately held medical technology company focused on women's reproductive health, announced that it initiated a multi-center clinical study to validate its early embryo viability assessment (Eeva™) System for use in in vitro fertilization (IVF). The Eeva System is designed to be used by embryologists to help identify, by day 3 of incubation, which embryos are most likely to continue development into blastocysts, a critical time point in human development that happens on day 5.

June 27, 2011

PRNewswire- June 27, 2011- MENLO PARK, CA- Auxogyn, Inc., a privately held medical technology company focused on women's reproductive health, today announced that the U.S. Patent and Trademark Office (USPTO) issued patent number 7,963,906 covering three predictive parameters for the assessment of embryo viability during in vitro fertilization (IVF) procedures used in Auxogyn's early embryo viability assessment (Eeva™) System.

October 4, 2010

PRNewswire- October, 4, 2010- MENLO PARK, CA- Auxogyn, Inc., a privately held medical technology company focused on women's reproductive health, today announced that it acquired an exclusive license from Stanford University to develop a set of products that may allow medical practitioners in the field of assisted reproduction to significantly improve the effectiveness of in vitro fertilization (IVF) procedures.